Figure 2: Mean CFT decrease was most pronounced in treatment naïve eyes ((b) from 675 μm [580; 810] to 238 μm [188; 348], change −437 μm, ) compared to Anti-VEGF_Dexamethasone group ((a) from 455 μm [323; 542] to 285 μm [219; 460], change −170 μm, ) and Dexamethasone_anti-VEGF treated eyes ((c) from 555 μm [395; 675] to 398 μm [245; 535], change −157 μm, ). A = CFT before switch from anti-VEGF to dexamethasone (a) or vice versa (c) or before treatment (b); B = CFT at the time of the best BCVA after switch/treatment (at 88 days [70; 176], 92 days [87; 100], and 123 days [96; 210]); and C = at the end of observation (median follow-up was 4.3 months for the Anti-VEGF_Dexamethasone group, 3.1 months for the Dexamethasone group, and 6.0 months for the Dexamethasone_anti-VEGF group).